The global regulatory affairs market size is expected to reach USD 26.0 billion by 2030, expanding at a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The factors expected to contribute to the growth of this market include changing regulatory requirements based on business activities and geographies, an increase in clinical trials & drug approvals along with accelerated regulatory approval, and technological advancement in regulatory software. Also, the evolution of personalized medicines, the increasing need for companies to focus on core business activities, and economic and competitive pressures are other factors that are contributing to the growth of the market.

The pharmaceutical and regulatory agencies joined forces to rapidly develop vaccines and medical products required to fight against the COVID-19 infection. The regulatory authorities take numerous precautions to ensure patient and personnel safety during a clinical trial, as well as data integrity and good laboratory practices are maintained. Growth in markets for biosimilars, orphan drugs, personalized medicines, companion diagnostics, and adaptive trial designs is projected to boost the demand for regulatory specialization in these areas. As companies venture into newer fields, the growing need to comply with regulations is boosting the demand for specialized service providers with expertise in regulatory affairs. Patent expiration of biologics, such as Simulect, Vectibix, Mircera, and Kineret, is increasing the demand and development of biosimilars, thereby contributing to the demand for regulatory services.

Gather more insights about the market drivers, restrains and growth of the Regulatory Affairs Market

Regulatory Affairs Market Report Highlights

• The outsourcing segment dominated the market with a share of 58.16% in 2023. The segment's growth is mainly due to the growing focus of pharmaceutical and medical device companies on outsourcing their activities, which allows them to access specialized expertise and resources they may not have in-house.

• The regulatory writing & publishing segment dominated the market, accounting for 36.41% of the global revenue in 2023.

• The medical devices segment dominated the market with a share of 41.05% in 2023. The segment's growth can be attributed to factors such as constant technological advancements and the increasing focus of market players on outsourcing medical device activities so they can focus more on their core competencies.

• The oncology segment dominated the market with a share of 32.77% in 2023. The growth of the segment is mainly due to the increasing prevalence of cancer, which requires effective and safe treatment options.

• Asia Pacific dominated the market and accounted for a 37.82% share in 2023. The growth in the region is attributed to factors such as an enhanced regulatory landscape, an increasing number of clinical trials, a growing number of pharmaceutical companies, and the availability of skilled workers in the region.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global tracheostomy products market size was estimated at USD 216.9 million in 2024 and is expected to grow at a CAGR of 4.3% from 2025 to 2030.

• The global radiodermatitis market size was estimated at USD 442.1 million in 2024 and is projected to grow at a CAGR of 4.0% from 2025 to 2030.

Regulatory Affairs Market Segmentation

Grand View Research has segmented the global regulatory affairs market on the basis of services, categories, indications, stages, types, company size, End Use, and region:

Regulatory Affairs Type Outlook (Revenue, USD Billion, 2018 - 2030)

• In-house

• Outsourced

Regulatory Affairs Services Outlook (Revenue, USD Billion, 2018 - 2030)

• Regulatory Consulting

• Legal Representation

• Regulatory Writing & Publishing

o Writing

o Publishing

• Product Registration & Clinical Trial Applications

• Other Services

Regulatory Affairs Categories Outlook (Revenue, USD Billion, 2018 - 2030)

• Drugs

o Innovator

o Preclinical

o Clinical

o Pre-Market Approval (PMA)

o Generics

o Preclinical

o Clinical

o Pre-Market Approval (PMA)

• Biologics

o Biotech

o Preclinical

o Clinical

o Pre-Market Approval (PMA)

o ATMP

o Preclinical

o Clinical

o Pre-Market Approval (PMA)

o Biosimilars

o Preclinical

o Clinical

o Pre-Market Approval (PMA)

• Medical Devices

o Diagnostics

o Preclinical

o Clinical

o Pre-Market Approval (PMA)

o Therapeutics

o Preclinical

o Clinical

o Pre-Market Approval (PMA)

Regulatory Affairs Indication Outlook (Revenue, USD Billion, 2018 - 2030)

• Oncology

• Neurology

• Cardiology

• Immunology

• Others

Regulatory Affairs Product Stage Outlook (Revenue, USD Billion, 2018 - 2030)

• Preclinical

• Clinical studies

• PMA

Regulatory Affairs Company Size Outlook (Revenue, USD Billion, 2018 - 2030)

• Small

• Medium

• Large

Regulatory Affairs End Use Outlook (Revenue, USD Billion, 2018 - 2030)

• Medical Device Companies

• Pharmaceutical Companies

• Biotechnology Companies

Regulatory Affairs Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

o U.S.

o Canada

o Mexico

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Denmark

o Norway

o Netherlands

o Switzerland

o Sweden

• Asia Pacific

o Japan

o China

o India

o Australia

o South Korea

o Indonesia

o Malaysia

o Singapore

o Thailand

o Taiwan

• Latin America

o Brazil

o Argentina

o Colombia

o Chile

• MEA

o South Africa

o Saudi Arabia

o UAE

o Egypt

o Israel

o Kuwait

Order a free sample PDF of the Regulatory Affairs Market Intelligence Study, published by Grand View Research.